All the cells in the body—healthy and cancerous—have HER2 receptors. But HER2+ breast cancer cells have too many HER2 receptors, which makes them grow and divide faster than other types of cells. This causes tumors to form.
Your doctor will know that your breast cancer is HER2+ by ordering a HER2 test. This test should be done before any breast cancer treatment is started. PHESGO has been shown to work only in people with HER2+ breast cancer.
You might have been told you have early breast cancer or metastatic breast cancer. You may even have experience with both.
If you have early breast cancer, that means the cancer started in the breast and has not spread to other parts of the body. However, cancer cells may also be in nearby glands called lymph nodes.
Metastatic breast cancer means the cancer has spread to other parts of the body, such as the lungs, liver, or bones.
PHESGO can be used for both early and metastatic, but each has a different treatment plan.
Not all HER2+ breast cancers are the same. Before recommending a treatment plan for you, your healthcare team will consider a number of other factors about your particular cancer, as well as your personal medical history and condition. This is because some treatments are more appropriate for different patients. Here are some of the things your healthcare team will look at:
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.